RE:RE:RE:RE:RE:RE:RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A DealsJanuary 31, 2023 - Pfizer gives guidance that its R&D program will include candidates targeting endocrine receptor-positive breast cancer.
ONCY's BRACELET-1 Phase 2 metastatic breast cancer study has been focused on endocrine receptor-positive (ER+)/HER2 negative breast cancer.
https://www.fiercebiotech.com/biotech/rd-still-lifeblood-pfizer-company-ups-rd-spend-plans-pursue-biotech-innovation